Titan Pharmaceuticals, Inc. (TTNP) |
7.3195 0.24 (3.38%) 04-19 16:00 |
Open: | 7.3195 |
High: | 7.3195 |
Low: | 7.3195 |
Volume: | 828 |
Market Cap: | 7(M) |
PE Ratio: | -0.99 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 9.29 |
Resistance 1: | 8.14 |
Pivot price: | 7.14 |
Support 1: | 6.28 |
Support 2: | 5.22 |
52w High: | 16.6 |
52w Low: | 5 |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
EPS | -7170000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | -74.074 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -3.00 |
Return on Assets (ttm) | 954.9 |
Return on Equity (ttm) | -74.9 |
Mon, 15 Apr 2024
Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com - Defense World
Thu, 25 Jan 2024
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria - Yahoo Finance
Fri, 29 Dec 2023
Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Markets Insider
Thu, 28 Dec 2023
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - Yahoo Finance
Wed, 13 Dec 2023
Selling Titan Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Mon, 18 Sep 2023
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |